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Abstract: (1) Background: Zinc is an essential micronutrient and zinc deficiency is associated with
immune dysfunction. The neonatal immune system is immature, and therefore an optimal neonatal
zinc status may be important. The aim of this study was to investigate the possible association
between neonatal whole blood (WB)-Zinc content and several immune markers. (2) Methods: In total,
398 healthy newborns (199 who later developed type 1 diabetes and 199 controls) from the Danish
Newborn Screening Biobank had neonatal dried blood spots (NDBS) analyzed for WB-Zinc content
and (i) cytokines: Interleukin (IL)-1β, IL-4, IL-6, IL-8, IL-10, IL-12 (p70), interferon gamma, tumor
necrosis factor alpha, and transforming growth factor beta; (ii) adipokines: leptin and adiponectin;
(iii) other immune response proteins: C-reactive protein (CRP), and mannose-binding lectin (MBL),
and soluble triggering receptors expressed on myeloid cells1 (sTREM-1). WB-Zinc content was
determined using laser ablation inductively coupled plasma mass spectrometry. For each analyte, the
relative change in mean level was modelled by a robust log-normal model regression. (3) Results:
No association was found between WB-Zinc content and all the immune response markers in either
the unadjusted or adjusted models overall or when stratifying by case status. (4) Conclusions: In
healthy Danish neonates, WB-Zinc content was not associated with cytokines, adipokines, CRP, MBL
or sTREM, which does not indicate a strong immunological function of neonatal zinc status.
Keywords: zinc; cytokines; adipokines; TREM1; C-reactive protein; mannose-binding lectin; infant;
newborn; immune system
1. Introduction
Zinc (Zn) is an essential trace metal for a plethora of metalloenzymes involved in growth, cognition,
reproduction, and immune function [1]. Zinc serves as an antioxidant through several mechanisms [2].
For examples, the zinc ion has a structural role in stabilizing copper/zinc superoxide dismutase, thereby
increasing the redox potential of copper ion (Cu (II)) resulting in the breakdown of free radicals, but
zinc is not redox active and cannot catalyze Fenton chemistry [3]. Further, zinc induces the cysteine-rich
zinc-binding protein metallothionein, which serves as an antioxidant [4].
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In Scandinavia, including in Denmark, approximately 6% of the population have inadequate
zinc intake [5], which is low compared to many African or middle Eastern countries [5]. The
primary reasons for zinc deficiency are inadequate dietary intake, impaired resorption [6], or increased
physiologic demands (e.g., pregnant women) [5,7]. Physiological plasma zinc levels are estimated to
be approximately 12–16 µM [8]. Zinc deficiency is associated with impaired growth and cognition [9],
dysregulation and impairment of both the adaptive and innate immune system [6,10,11], systemic
inflammation [11], and increased susceptibility to infectious diseases [6]. These harmful effects have
fortunately been shown to be reversible, as zinc supplementation restores or even improves immune
function [6].
In an observational study of adults, increases in serum zinc are inversely associated with C-reactive
protein (CRP), interleukin 6 (IL-6), and tumor necrosis factor alpha (TNF-α) [12]. In randomized trials,
zinc supplementation has been shown to decrease the incidence of infections in the elderly [13] and
reduce morbidity and mortality in preterm neonates [14]. In the elderly, zinc supplementation decreases
markers of oxidative stress (such as 8-oxodGuo, malondialdehyde, and 4-hydroxyalkenals) [13,15],
the chronic inflammatory marker CRP [15], and the inflammatory cytokine IL-6 [15], and increases
interleukin 2 (IL-2) which is important for cell-mediated immune responses [13]. In a study of Mexican
children aged 6–7 years old, with plasma zinc within the reference range, a supplementation of zinc
and other micronutrients increased the ex vivo monocyte generation of IL-2 and interferon gamma
(IFN-γ) and decreased the generation of IL-10 compared to before supplementation [16]. In Indonesian
infants aged 3–10 months old, stimulated ex vivo IL-6 production was decreased in zinc-deficient
infants compared to non-deficient infants [17].
Proinflammatory cytokines (such as IFN-γ, TNF-α, and interleukin 1β (IL-1β)) promote beta-cell
destruction and exacerbate autoimmunity, which may ultimately lead to type 1 diabetes (T1D) [18]. It is
debatable whether zinc deficiency is associated with T1D [19,20]. However, no study has investigated
the association between immune response markers and zinc status in healthy newborns who later
develop T1D and newborns who do not.
The neonatal immune system is immature, and it is well known that adaptive immune responses
are deficient in early life. Further, there are numerous significant deficiencies of the innate immune
system in neonatal life. The consequence of this is increased susceptibility to infections, and therefore
increased mortality and morbidity in early life [21]. Environmental exposures in the perinatal
period, such as nutrients, are shown to induce changes in immune function [22]. As zinc deficiency
compromises the immune system, it is relevant to investigate the association between zinc status
in healthy/non-infected newborns and a large number of cytokines, adipokines and other immune
response proteins. Therefore, this study aimed to investigate this association using neonatal whole
blood zinc (WB-Zinc) content in dried blood spots from the Danish Newborn Screening Biobank
(DNSB). This study may lead to better insight into the role of zinc in the perinatal immune system.
2. Materials and Methods
2.1. Study Design and Sampling
This population study is based on a case-cohort design from the DNSB, located at Statens Serum
Institut, Copenhagen, Denmark. Newborn dried blood spots (NDBSs), from children born in Denmark
between January 1991 and November 1998, were taken as capillary blood samples from the newborn’s
heel, 5–7 days after birth, and immediately transferred to filter paper. NDBSs offer screening of
several diseases in Danish newborns. The NDBSs are stored at −20 ◦C/−4 ◦F in the DNSB. This
biobank includes close to 100% of the NDBSs of Danish newborns since 1982 [23]. The DNSB is mostly
comprised of Danish ethnic children. In a study (n = 3956), ~94% of the newborns had mothers of
Danish origin, 1.4% had mothers from other western countries and the remaining newborns had
mothers from non-western countries [24].
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Individuals were randomly selected from an original case-control study, conducted by our
research group, aiming at examining predictors of childhood and adolescent T1D [25]. The focus of the
current study is the association between zinc and a large number of cytokines, adipokines and other
immune response proteins in healthy/non-infected newborns. Cases were those who later developed
T1D, and controls were those who did not. Briefly, T1D diagnoses were retrieved from the Danish
National Patient Registry based on International Classification of Diseases (ICD )codes (ICD-8 249 and
250. ICD-10 DE 10.x–14.x) and were cross-validated using the Danish Childhood Diabetes Registry
(DanDiabKids) to secure a T1D diagnosis [26]. DanDiabKids, established in 1996, is a nationwide
register, collecting data from all Danish pediatric diabetes clinics treating patients with T1D aged
0–18 years.
Cases were matched with controls based on date of birth. In total, 398 participants (199 cases
and 199 controls) were included in the study, though 17 controls and 1 case were excluded from the
primary pre-selected analysis due to missing covariate data (Figure 1).
Figure 1. Flow chart of participants included in the study and different models.
2.2. Exposure Assessment
Assessment of Whole Blood Zinc Content
The NDBSs, measuring 3.2 mm in diameter and containing ~3.4 µL of dried capillary blood,
from each participant, were analyzed for zinc (66Zn) using laser ablation inductively coupled plasma
mass spectrometry (LA-ICP-MS) [19]. Additionally, the NDBSs were analyzed for potassium (39K)
in the same run. 39K was used to adjust for possible differences in blood volume in the NDBSs and
the hematocrit value in the newborn [27,28]. The NDBSs were analyzed by continuous line scans
through the center of each sample, 12 consecutive points on each NDBS, which aimed to increase the
precision of the WB-Zinc content. All of the samples were analyzed in the same analytical run, thereby
minimizing operational variation.
During the study period (1991–1998) the American filter paper 903 (Whatman BFR, St. Louis,
MO, USA) were used. By only including cases and controls from this period, we removed the risk of
including filter paper, by different manufacturers, with possible zinc content differences. For further
details regarding analytic setup, see Kyvsgaard et al. [19].
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2.3. Outcome Assessment
The NDBSs were analyzed using a multiplexed sandwich immunoassay based on flowmetric
Luminex xMAP® technology, which can measure up to 25 inflammatory markers simultaneously
on NDBSs [29]. The following analytes were quantified: (i) cytokines; IL-1β, IL-4, IL-6, IL-8, IL-10,
IL-12 (p70), IFN-γ, TNF-α, and transforming growth factor beta (TGF-β); (ii) adipokines; leptin and
adiponectin; and (iii) other immune response proteins: CRP and mannose-binding lectin (MBL)
involved in innate immunity, and soluble triggering receptor expressed on myeloid cells1 (sTREM-1)
belonging to the immunoglobin superfamily.
In all assays, matched pairs were run together to avoid batch effects/interassay variation [30].
Biomarker analyses are described in detail elsewhere [29]. Quality control of the analysis was made
using mouse IL-6 as an internal analyte added to the extraction buffer to detect pipetting errors, and
biotinylated beads to detect signal errors (a more detailed description are found in Skogstrand [31]).
Calibration curves were used on each plate together with one high and two low controls. Samples,
calibrators, and controls were analyzed in duplicates.
The absolute levels of the cytokines, adipokines and other proteins involved in the immune
response stratified by case status are presented elsewhere [32].
2.4. Other Variables
A number of descriptive variables and possible confounders were available for inclusion in our
analyses. These variables are listed and the coding of them is presented in Table 1.
Table 1. Characteristics of the study sample (including specification of missing values). Cases are
children who developed childhood type 1 diabetes (T1D), and controls who did not develop T1D
during childhood.




Female, n/% of total 103/51.8 95/47.7
Gestational age 2,
Median/interquartile range (IQR), weeks 40.0/1.0 40.0/2.0
Birth weight 3,
Median/IQR, grams 3500/630 3500/744
Maternal age 4,
Median/IQR, years 29.0/6.0 28.0/8.0





Period of blood sampling, n/% from total
1991–1993 109/54.8 109/54.8
1994–1998 90/45.2 90/45.2
Human leukocyte antigen (HLA)-risk groups 5, n/%
from total
High/moderate 6 151/82.5 68/40.0
Low/protective 7 32/17.5 102/60.0
Missing data (n/% of total): 1 11/2.8, 2 17/4.3, 3 24/6.0, 4 11 17/4.3, and 5 45/11.3. HLA-DQB1 genotype (allele_1/allele_2):
6 03:02/99:99, 03:02/02, 06:04/03:02, 03:01/02, 06:03/03:02, 02/99:99, 06:04/02, 06:04/99:99, 03:01/03:02. 06:04/03:04, and.
7 06:02/03:02, 06:02/99:99, 06:02/02, 06:03/99:99, 03:01/99:99, 06:02/03:01, 06:03/03:01, 06:04/03:01, 06:03/02, 03:04/99:99,
03:04/02, 06:02/03:04, 99:99/99:99. Note bene: 99:99 = remaining alleles.
Nutrients 2019, 11, 1980 5 of 11
2.5. Statistical Analysis
The random sampling of 400 individuals (200 cases and 200 controls) from the larger cohort of
2086 cases and 4172 controls [25] was performed by a random number generator in Statistical Analysis
Software (SAS) version 9.3 using the floor-statement and was performed on the cases born from
1991–1998 (as the same filter paper was used in this period). Each case was originally matched with 2
controls based on date of birth but, for this nested study, we only included the first control found for
each case.
Neonatal WB-Zinc content was log2-transformed, due to a log-normal distribution. Results are
therefore interpreted as relative change (RC) in mean levels of immune response markers for each
doubling in neonatal WB-Zinc content. We analyzed the data overall and stratified by case status.
Neonatal WB-Zinc content was modeled by a robust log-normal model regression, taking into
account: (i) that measurements are potentially both left and right censored; and (ii) correlation within
immunoassay. To account for correlation within the immunoassay, an inference was based on a
working independence generalized estimation equation (GEE) approach.
The simultaneous evaluation of neonatal WB-Zinc content on all analytes was performed using
the model stacking approach detailed in Pipper et al. [33].
Subsequent adjustment for multiple testing and familywise 95% confidence bands (95% CI) were
calculated using the single-step procedure by Hothorn et al. [34]. GEE estimates of mean ratios
and accompanying confidence limits were calculated on a log-scale and transformed back to the
original scale.
Model selection was performed prior to statistical analyses based on our previous work using these
data: (i) univariate models; and (ii) primary adjusted models using possible confounders (covariates
associated with neonatal WB-Zinc content (birth weight and birth year), see Kyvsgaard et al. [19]). Due
to the construction of our study sample, we also included case status in the multivariate models.
Overall functional misspecification by including neonatal WB-Zinc content as a trend (linear
variable) was assessed by a lack-of-fit test. Specifically, we included a quadratic term of neonatal
WB-Zinc content and tested its significance by a robust Wald test.
p-values were evaluated at the two-sided 5% significance level and we decided prior to our
statistical analyses both to include results with and without adjustment for multiple testing.
All analyses were made using the statistical software package R version 3.5.1 (the R foundation
for statistical programming, Vienna, Austria) and the add-on packages, survival and multcomp.
2.6. Ethics
The study was performed in accordance with the Helsinki II Declaration. Furthermore, the study
was approved by the Danish Ethical Committee (H-2-2014-007) and by the DNSB Steering Committee.
According to Danish law, anonymous studies do not require further informed consent.
3. Results
Characteristics of the study population are presented in Table 1. The overall median (Q1, Q3)
neonatal WB-Zinc content was 1.880 × 10−3 (1.142 × 10−3, 2.545 × 10−3) units.
3.1. Unadjusted Models and Adjusted Models
No association between neonatal WB-Zinc content and cytokines, adipokines and other proteins
involved in immune response were found in the unadjusted and adjusted analyzes without correction
for multiple testing (Table 2). Results remained the same after correction for multiple testing
(Supplementary Table S1). Non-linear models were considered for the above-mentioned primary
exposures. A quadratic term did not improve model fit, and so these exposures were retained as
linear predictors.
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Table 2. Relative change in mean neonatal levels of cytokines, adipokines and other proteins involved
in the immune response with 95% confidence bands linked with every doubling in neonatal whole
blood zinc content—results from models without correction for multiple testing.
Outcome Variable Univariate Model p-Value Multivariate Model p-Value
IL-1β WB-Zinc content 1.00 (0.89; 1.12) 1.00 0.97 (0.87; 1.09) 0.64
IL-4 WB-Zinc content 0.99 (0.92; 1.06) 0.73 0.97 (0.90; 1.04) 0.37
IL-6 WB-Zinc content 1.08 (0.99; 1.19) 0.10 1.07 (0.96; 1.19) 0.21
IL-8 WB-Zinc content 0.98 (0.92; 1.04) 0.49 1.02 (0.97; 1.07) 0.52
IL-10 WB-Zinc content 0.98 (0.83; 1.16) 0.81 1.01 (0.86; 1.19) 0.91
IL-12 WB-Zinc content 1.08 (0.98; 1.20) 0.12 1.02 (0.93; 1.12) 0.61
IFN-γ WB-Zinc content 1.02 (0.93; 1.11) 0.71 1.02 (0.92; 1.12) 0.73
TNF-α WB-Zinc content 1.07 (0.98; 1.16) 0.15 1.01 (0.93; 1.10) 0.85
TGF-β WB-Zinc content 1.06 (0.97; 1.14) 0.20 1.01 (0.93; 1.09) 0.83
Adiponectin WB-Zinc content 1.02 (0.96; 1.10) 0.50 0.99 (0.93; 1.06) 0.86
Leptin WB-Zinc content 0.97 (0.90; 1.05) 0.48 0.99 (0.93; 1.07) 0.90
CRP WB-Zinc content 0.91 (0.82; 1.01) 0.08 0.97 (0.87; 1.08) 0.55
MBL WB-Zinc content 1.04 (0.93; 1.17) 0.44 1.05 (0.93; 1.18) 0.41
sTREM-1 WB-Zinc content 0.99 (0.89; 1.11) 0.90 0.95 (0.85; 1.05) 0.31
Bold letters indicate significance at the two-sided 5% level. Covariates included in the multivariate models are
neonatal whole blood Zinc (WB-Zinc) content, case status (cases are children who developed childhood type 1
diabetes (T1D), and controls who did not develop T1D during childhood), birthweight and period. IL, interleukin;
IFN-γ, interferon gamma; TNF-α, tumor necrosis factor alpha; TGF-β, transforming growth factor beta; CRP,
c-reactive protein; MBL, mannose-binding lectin; sTREM-1, soluble triggering receptor expressed on myeloid cells.
3.2. Unadjusted Models with Statification on Case Status
We found no signs of effect modification by case status (neonates who later developed T1D versus
neonates who did not) on our main effects. Results are presented in Table 3.
Table 3. Relative change in mean neonatal levels of cytokines, adipokines and other proteins involved
in the immune response with a 95% confidence bands linked with every doubling in neonatal whole
blood zinc content—results from univariate models with stratification by case status and no correction
for multiple testing.
Outcome Variable Univariate Model(Cases) p-Value
Univariate Model
(Controls) p-Value
IL-1β WB-Zinc content 0.97 (0.83; 1.14) 0.74 1.03 (0.89; 1.20) 0.66
IL-4 WB-Zinc content 0.99 (0.90; 1.09) 0.86 0.98 (0.90; 1.08) 0.71
IL-6 WB-Zinc content 1.12 (0.99; 1.26) 0.84 1.05 (0.91; 1.22) 0.50
IL-8 WB-Zinc content 0.99 (0.91; 1.08) 0.80 0.97 (0.90; 1.05) 0.43
IL-10 WB-Zinc content 0.97 (0.76; 1.22) 0.78 0.99 (0.78; 1.27) 0.96
IL-12 WB-Zinc content 1.07 (0.95; 1.20) 0.25 1.10 (0.96; 1.26) 0.17
IFN-γ WB-Zinc content 1.04 (0.92; 1.16) 0.54 0.99 (0.87; 1.14) 0.94
TNF-α WB-Zinc content 1.03 (0.91; 1.17) 0.61 1.11 (0.99; 1.24) 0.08
TGF-β WB-Zinc content 1.04 (0.95; 1.13) 0.40 1.07 (0.95; 1.21) 0.24
Adiponectin WB-Zinc content 1.00 (0.94; 1.07) 0.95 1.05 (0.94; 1.18) 0.38
Leptin WB-Zinc content 0.98 (0.88; 1.08) 0.66 0.98 (0.89; 1.06) 0.57
CRP WB-Zinc content 0.93 (0.81; 1.07) 0.32 0.88 (0.76; 1.04) 0.13
MBL WB-Zinc content 1.05 (0.89; 1.24) 0.59 1.04 (0.88; 1.24) 0.65
sTREM-1 WB-Zinc content 0.95 (0.82; 1.10) 0.49 1.05 (0.91; 1.20) 0.51
Case status (cases are children who developed childhood type 1 diabetes (T1D) and controls who did not develop
T1D during childhood). IL, interleukin; IFN-γ, interferon gamma; TNF-α, tumor necrosis factor alpha; TGF-β,
transforming growth factor beta; CRP, c-reactive protein; MBL, mannose-binding lectin; sTREM-1, soluble triggering
receptor expressed on myeloid cells-1.
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4. Discussion
In this study, we did not find any association between neonatal WB-Zinc content and levels of
cytokines (i.e., IL-1β, IL-4, IL-6, IL-8, IL-10, IL-12 (p70), IFN-γ, TNF-α, and TGF-β), adipokines (i.e.,
leptin and adiponectin) and other proteins involved in the immune response (i.e., CRP, MBL, and
sTREM-1) in healthy newborns. These are novel findings.
4.1. Comparison with Other Studies
A randomized controlled trial included newborns with sepsis, and one group was
zinc-supplemented (i.e., 3 mg/kg of zinc sulfate monohydrate twice a day orally for 10 days) on
top of standard treatment with antibiotics (n = 134, age < 28 days). The zinc-supplemented group of
neonates had significantly higher serum zinc levels and a significant decline in the concentration of the
inflammatory cytokines IL-6 and TNF-α. The control group only had a significant reduction in IL-6
after treatment with antibiotics. Mortality was lower in the zinc group, though it was not statistically
significant (p = 0.12) [35]. This study suggests that zinc has anti-inflammatory properties. The study
differs from ours by including infected newborns and by using zinc supplementation as intervention.
Zinc supplementation lead to a higher variation in serum zinc levels between the two groups of
newborns, thereby increasing the power and limiting the risk of type 2 errors (false negative results). A
murine study found that the IL-6 functions as an enhancer of the zinc importer zinc transporter protein
(Zrt)-, iron-regulated transporter (Irt)-related protein (ZIP)14 expression on hepatocytes, resulting in
lower plasma concentrations of zinc when inflammation was induced [36].
A study, which included a cohort of healthy breast-fed Indonesian infants, had their serum zinc
analyzed at age 3, 6 and 9 months. Further, biomarkers for inflammation (i.e., CRP andα-1-glycoprotein)
were measured. This study showed that infants with lower zinc status had higher CRP levels. This
study also highlights that zinc deficiency is overestimated when the infants are in a condition with
inflammation [9], which, as mentioned above, may be mediated by IL-6, etc. [36]. We could not
confirm an association between levels of neonatal WB-Zinc content and CRP, perhaps due to the
differences in age between our studies. At 3–9 months of age, zinc status is primarily dependent on the
infant’s diet and not dependent on the mother’s nutritional status, as is the case when a fetus [37]. In
addition, the cohort of infants were from Indonesia, where approximately 30% of the population have
an inadequate zinc intake, compared to only 6% in Scandinavia [5]. Maternal zinc status is dependent
on the nutritional status and/or chronic infection [38]. Maternal zinc deficiency can lead to a reduction
in placental zinc transport to the fetus, thereby inducing zinc deficiency in the fetus. However, this is
only observed when the maternal zinc deficiency is severe due to the fact that the active transport of
placental zinc to the fetus is maintained even though maternal zinc levels are lowered [1].
A study, including 88 healthy mothers who gave birth to healthy newborns with a gestation age of
38–42, showed that maternal serum leptin levels were positively correlated with maternal zinc levels.
However, serum leptin levels in cord blood were not found to be associated with serum zinc in cord
blood [39]. The latter result is in line with findings from our study.
In elderly individuals, zinc supplementation decreases circulating inflammatory cytokines, CRP
and other plasma oxidative stress markers [12,13,15]. A randomized, double-blind, placebo trial
included healthy elderly individuals (n = 40, aged 56–83). The intervention group received 45 mg
zinc/day for 6 months, which lead to an increase in plasma zinc, and a decrease in CRP and IL-6
levels [15]. A similar randomized, double-blind, placebo-controlled study included healthy elderly
individuals (n = 50, aged 55–87). The intervention group received 45 mg zinc/day in total in 12 months.
Zinc supplementation lead to a significantly lower incidence of infections, an increase in plasma zinc,
and a decrease in TNF-α levels and oxidative stress markers [13]. Further, this study showed that
older individuals had significantly lower plasma zinc and increased oxidative stress compared with
a group of younger adults (n = 31, aged 18–54) [13]. Furthermore, a cross-sectional study included
healthy Rural Korean Adults (n = 1,055 i.e., 404 men and 651 women, aged > 40). These subjects had
their dietary zinc intake analyzed. No significant inverse relationship between dietary zinc intake
Nutrients 2019, 11, 1980 8 of 11
and inflammatory cytokines/markers IL-6, TNF-α, and CRP were shown [12]. These studies [12,13,15]
suggest that the elderly population differ from newborns due to the increased level of oxidative stress
and higher risk of zinc deficiency, which can explain why studies that include elderly individuals
are able to show a significant decrease in levels of inflammatory cytokines and other inflammatory
markers when zinc supplemented. Further, randomized controlled trials are more powerful compared
to observational study designs.
4.2. Strengths and Limitations
This study is larger than many of the studies previously published on the association of early life
zinc exposure and immune response markers [9,14,16,17,35,39]. Further, we report findings from a
population of neonates with no sign of serious infections (CRP range of 0.01–20.1 mg/L). A limitation is
pre-analytical factors, which could falsely elevate levels of zinc, such as hemolysis, starvation, and
diurnal variation [1]. In particular, dried blood spots are prone to hemolysis and, unfortunately, we
did not have serum values. The zinc level for each participant was divided with the potassium level,
thereby adjusting for hematocrit, thereby limiting hemolysis bias [28]. The study is cross-sectional
without serial data on zinc and cytokines, adipokines and other proteins involved in the immune
response, which could have given further information on long-term associations. Also, we did not
have information on the mothers’ zinc or nutritional status, thereby we were not able to investigate
the link between the mothers’ and newborns’ zinc status and immune response. A reason for why
no associations were found might be due to the fact that zinc deficiency is rare in Denmark ~ 6% [5],
but our intent was also to examine associations within the normal physiological span. Residual
confounding cannot be excluded either.
4.3. Future Perspective
No link between neonatal WB-Zinc content and cytokines, adipokines and proteins involved in
the immune response was found in this study of healthy neonates. In future research, it would be
interesting to conduct serial analyses of zinc status including other micronutrients during pregnancy
and in the neonatal period in relation to immune response markers, due to possible complex interactions
between micronutrients and the immune system. It may be relevant to include subgroups of newborns
with an increased risk of zinc deficiency (i.e., premature [1,40]) or newborns with low birth weight [41]
in future research.
5. Conclusions
In healthy/non-infected neonates, WB-Zinc content was not correlated to cytokines, adipokines,
CRP, MBL or sTREM-1.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/9/1980/s1,
Table S1: Relative change in mean neonatal levels of cytokines, adipokines and other proteins involved in
the immune response with 95% confidence bands linked with every doubling in neonatal whole blood zinc
content—results from models with correction for multiple testing.
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